Here is Why Doximity (DOCS) Still Appears Attractive

Doximity Inc. (NYSE:DOCS) is one of the 7 oversold stocks to buy with double-digit ROE growth.

On April 8, Elizabeth Anderson from Evercore ISI downgraded Doximity Inc. (NYSE:DOCS) to In Line from Outperform with a price target from $30 to $25. The reasons for the downgrade, as highlighted by the analyst, included lower-than-expected forecasted growth in the market for 2026, competitive risk, and a fair valuation.

VILevi/Shutterstock.com

Anderson further stated that there has been low organic growth in the high single digits in Doximity’s fiscal year 2026 due to a decline in pharmaceutical advertising, which has not kept pace with R&D spend.

On March 17, Doximity Inc. (NYSE:DOCS) issued a detailed report examining how medical professionals throughout the United States are integrating AI into clinical practice. This report is the result of extensive research conducted between March 2025 and January 2026 with 3151 physicians from 15 different specialties.

According to the research, 94% of physicians either use these cutting-edge solutions now or are strongly inclined towards using them. Furthermore, 71% of practitioners stated that their primary operational concerns were accuracy and reliability. According to management, in order to successfully reduce administrative expenses, improve employee satisfaction, and increase direct patient care time at the existing level, strong physician engagement and transparent development are required.

Doximity Inc. (NYSE:DOCS) is a digital platform offering online networking services to healthcare and medical professionals. The company has an extensive network currently covering around 80% of U.S.-based physicians. Their AI-powered application helps in efficient HIPAA-compliant communication among healthcare professionals.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.